ALLARITY THERAPEUTICS, INC.
Last · NASDAQ$0.8733+0.0033 (+0.38%)close · yahoo · 11h ago
Market cap$13.89M15.9M sh
P/E · TTM-1.1fwd -1.0 · eps -0.79 · loss
Beta0.57vs S&P 500
Div yield0.00%annual · TTM
52w range
$0.769$1.84
Volume64.0Ksession
Loading chart…
OpenFilings analyst
Our analyst
From latest 10-K · 2026-03-30
- Sbc Revenue High
- Operating Cf Burn
- Net Margin Sharply Negative
- Cash Conversion Weak
- Cash Runway Low
- Accumulated Deficit High
- Rd Intensity High
Red flags
- Sbc Revenue High — SBC/Revenue 150.6%
- Operating Cf Burn — Negative operating cash flow
- Net Margin Sharply Negative — Net margin -3509.7%
- Cash Conversion Weak — Cash conversion (CFO/Rev) -4631.2%
- Cash Runway Low — Cash runway ~1.0 years
- Accumulated Deficit High — Accumulated deficit / equity 1325%
- Rd Intensity High — R&D/Revenue 2062.8%
Press & signals
- GlobeNewswire
Allarity Therapeutics Expands Laboratory Capabilities to Include Proteomics and Cell Line Research
- GlobeNewswire
Allarity Therapeutics Granted Japanese Patent for Stenoparib DRP® Companion Diagnostic, Further Strengthening Stenoparib Development
- GlobeNewswire
Allarity Therapeutics Announces Strategic Capital Allocation for Filing of SPAC Registration Statement
The rest of this company's wire — with summaries and source links — is part of Pro.
See plansDocuments
FormReporting forFiledFlags